Skip to main content

Table 4 Efficacy of first-line anti-malarials in three therapeutic efficacy monitoring sites in Angola, 2015

From: Efficacy of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015

 

Efficacy (95% confidence intervals)

Benguela

Zaire

Lunda Sul

ASAQa

ALa

ALa

DPb

DPb

ASAQa

Uncorrected

 Per-protocol Day 28

90.4 (81–96)

89.4 (80–95)

75.3 (65–83)

95.6 (88–99)

100 (94–100)

100 (92–100)

 Per-protocol Day 42

81.9 (72–89)

100 (94–100)

 Kaplan–Meier estimate Day 28

90.3 (84–97)

89.6 (83–96)

76.0 (68–85)

95.5 (91–100)

100

100

 Kaplan–Meier estimate Day 42

82.5 (75–91)

100

PCR-corrected

 Per-protocol Day 28

99.9 (95–100)

96.1 (89–99)

86.5 (77–92)

98.8 (94–99)

100 (96–100)

100 (94–100)

 Per-protocol Day 42

98.5 (92–99)

100 (96–100)

 Kaplan–Meier estimate Day 28

99.9 (95–100)

96.3 (91–100)

88.1 (81–95)

98.8 (96–100)

100

100

 Kaplan–Meier estimate Day 42

98.8 (96–100)

100

  1. Per-protocol efficacy defined as proportion adequate clinical and parasitological response (ACPR), Kaplan–Meier estimate calculated from estimate of survival function
  2. ASAQ artesunate–amodiaquine, AL artemether–lumefantrine, DP dihydroartemisinin–piperaquine
  3. a28-day follow up
  4. b42-day follow up